Efficacy of exercise in reducing depressive symptoms across 5-HTTLPR genotypes

Medicine and Science in Sports and Exercise

Volumn 42, Issue 11, 2010, Pages 2141-2147

  Rethorst, Chad D ^a   Landers, Daniel M ^b   Nagoshi, Craig T ^b   Ross, Julianna T D ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

depression; negative life stress; Physical activity; serotonin transporter gene

Indexed keywords

SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SLC6A4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; EXERCISE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; DEPRESSION; EXERCISE; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; QUESTIONNAIRES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78049529328     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e3181de7d51     Document Type: Article

References (51)

1. Andrews G, Sanderson K, Corry J, Lapsley HM. Using epide-miological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ. 2000;3(4):175-86.
2. Anthony J, Sexton T, Neumaier J. Articles-antidepressant-induced regulation of 5-HT1B mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res. 2000;61(1):82-7.
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4: 561-71.
4. Broadhead W, Blazer D, George L, Tse C. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264(19):2524-8.
5. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale (NJ): Lawrence Erlbaum.
6. Craft LL, Landers DM, Jackson SA, et al. The effect of exercise on clinical depression and depression resulting from mental illness: a meta-analysis. J Sport Exerc Psychol. 1998;20(4):339-57.
7. David SP, Murthy NV, Rabiner EA, et al. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci. 2005;25(10):2586-90.
8. Dechant KL, Clissold SP. Paroxetine. A review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41(2):225-53.
9. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. 1989; 46(11):971-82; discussion 983.
10. Figueras G, Pérez V, San Martino O, Alvarez E, Artigas F. Pre-treatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Biol Psychiatry. 1999; 46(4):518-24.
11. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequi-libria in African-and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet. 1997;101(2): 243-6.
12. Greenwood BN, Foley TE, Day HEW, et al. Wheel running alters serotonin (5-HT) transporter, 5-HT1A, 5-HT1B, and alpha1b-adrenergic receptor mRNA in the rat raphe nuclei. Biol Psychiatry. 2005;57(5):559-68.
13. Heils A, Teufel A, Petri S, et al. Allelic variation of the human serotonin transporter gene expression. J Neurochem. 1996;66(6): 2621.
14. Hughes CW, Petty F, Sheikha S, Kramer GL. Whole-blood serotonin in children and adolescents with mood and behavior disorders. Psychiatry Res. 1996;65(2):79-95.
15. Jacobs BL. Serotonin, motor activity and depression-related disorders. Am Sci. 1994;82:456-63.
16. Judd LL, Paulus MP. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry. 1996;153:1411-7.
17. Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry. 1994;55(suppl):18-28.
18. Karege F, Widmer J, Bovier P, Gaillard JM. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. Neuropsychopharmacology. 1994;10(3): 207-14.
19. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. Br Med J. 2001;322(7289):763.
20. Le Poul E, Boni C, Hanoun N, et al. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology. 2000; 39(1):110-22.
21. Lesch KP. Serotonergic gene expression and depression: implications for developing novel antidepressants. J Affect Disord. 2001; 62(1-2):57-76.
22. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527.
23. Lesch KP, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res Mol Brain Res. 1993;17(1-2):31-5.
24. Lyness JM, Kim JH, Tang W, et al. The clinical significance of subsyndromal depression in older primary care patients. Am J Geriatr Psychiatry. 2007;51:1554-62.
25. McCann IL, Holmes DS. Influence of aerobic exercise on depression. J Pers Soc Psychol. 1984;46(5):1142-7.
26. McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. Psychol Aging. 1991;6(3):487-8.
27. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT2A receptors in depression: an [18F] setoperone PET imaging study. Am J Psychiatry. 2001;158(1):78.
28. Moreno J, Campos MG, Lara C, et al. Tryptophan and serotonin in blood and platelets of depressed patients. Effect of an antide-pressant treatment. Salud Ment. 2006;29(4):1.
29. Muck-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepres-sant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord. 1991; 23(3):157-64.
30. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. In: Global Burden of Disease and Injury Series (Vol. 1). Boston: Harvard University Press; 1996. p. 1-900.
31. Nathan PE, Gorman JM. A Guide to Treatments that Work. New York: Oxford University Press; 2007. 271-308.
32. Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology. 1996;15(5):515-22.
33. North TC, McCullagh P, Tran ZVU. Effect of exercise on depression. Exerc Sport Sci Rev. 1990;18(1):379.
34. Owens M, Nemeroff C. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994; 40(2):288-95.
35. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. Focus. 2008;6(1):155.
36. Rethorst CD, Wipfli BM, Landers DM. The antidepressive effects of exercise: a meta-analysis of randomized trials. Sports Med. 2009;39(6):491.
37. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, ser-traline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-42.
38. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol. 1978;46(5):932-46.
39. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247.
40. Singh N, Clements K, Fiatarone M. A randomized controlled trial of progressive resistance training in depressed elders. J Gerontol A Biol Med Sci. 1997;52(1):27-35.
41. Skodol A, Schwartz S, Dohrenwend B, Levav I, Shrout P. Minor depression in a cohort of young adults in Israel. Arch Gen Psychiatry. 1994;51(7):542-51.
42. Smeraldi E, Zanardi R, Benedetti F, Bella DD, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3(6):508-11.
43. Stathopoulou G, Powers MB, Berry AC, Smits JAJ, Otto MW. Exercise interventions for mental health: a quantitative and qualitative review. Clin Psychol. 2006;13(2):179-93.
44. Struder HK, Hollman W, Platen P, Wostmann R, Weicker H, Molderings GH. Effect of acute and chronic exercise on plasma amino acids and prolactin concentrations and on [3H] ketanserin binding to 5-HT2A receptors on human platelets. Eur J Appl Physiol. 1999;79(4):318-24.
45. Swan MC, Rahman NA, Bennett JP. Expression of serotonin transporter mRNA in rat brain: Presence in neuronal and non-neuronal cells and effect of paroxetine. J Chem Neuroanat. 1997;13(2):71-6.
46. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
47. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28.
48. Williams RB, Marchuk DA, Gadde KM, et al. Central nervous system serotonin function and cardiovascular response to stress. Psychosom Med. 2001;63(2):300-5.
49. Wipfli B, Landers D. An examination of serotonin and psychological variables in the relationship between exercise and mental health. Scand J Med Sci Sports. in press.
50. Zanardi R, Benedetti F, Daniela Di Bella MD, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000;20(1):105.
51. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support. J Pers Assess. 1988;52(1): 30-41.